11,610 Shares in Sanofi (NASDAQ:SNY) Bought by Unique Wealth Strategies LLC

Unique Wealth Strategies LLC purchased a new position in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,610 shares of the company’s stock, valued at approximately $577,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Rise Advisors LLC grew its holdings in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares in the last quarter. Salem Investment Counselors Inc. acquired a new position in Sanofi during the 4th quarter worth $27,000. Venturi Wealth Management LLC grew its holdings in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after acquiring an additional 332 shares in the last quarter. CNB Bank acquired a new position in shares of Sanofi in the 3rd quarter valued at about $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA boosted its holdings in shares of Sanofi by 115.6% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of several research reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Morgan Stanley initiated coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $55.00.

Sanofi Stock Performance

Sanofi stock traded down $0.23 during midday trading on Friday, reaching $49.13. 4,148,180 shares of the stock traded hands, compared to its average volume of 2,214,580. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $47.71 and a two-hundred day moving average price of $48.37. The firm has a market cap of $124.28 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 1.48 and a beta of 0.61. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $56.26.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. On average, equities research analysts forecast that Sanofi will post 4.09 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s payout ratio is 69.35%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.